T Jiang1, B J Wei2,3, D X Zhang4, L Li5, G L Qiao6, X A Yao1, Z W Chen7, X Liu7, X Y Du7. 1. Department of Endocrinology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. 2. Department of Otorhinolaryngology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. cywbj1015@sina.com. 3. Department of Thyroid and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. cywbj1015@sina.com. 4. Department of Endocrinology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. 407558653@qq.com. 5. Department of Pediatric Surgery, Capital Institute of Pediatrics, Beijing, 100020, China. lilong23@126.com. 6. Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China. 7. Department of Medical Genetics and Developmental Biology, Capital Medical University, Beijing, 100069, China.
Abstract
Diagnosis of parathyroid carcinoma on histological examination is challenging. Thousands of differentially expressed lncRNAs were identified on the microarray data between parathyroid cancer and adenoma samples. Four lncRNAs were significantly dysregulated in further validation. The "lncRNA score" calculated from these lncRNAs differentiated parathyroid carcinomas from adenomas. LncRNAs serve as biomarkers for parathyroid cancer diagnosis. INTRODUCTION: Diagnosis of parathyroid carcinoma (PC) on histological examination is challenging. LncRNA profile study was conducted to find diagnostic biomarkers for PC. METHODS: LncRNA arrays containing 91,007 lncRNAs as well as 29,857 mRNAs were used to assess parathyroid specimen (5 carcinomas and 6 adenomas). Bioinformatics analyses were also conducted to compare the microarray results between parathyroid carcinomas and adenomas (PAs). Differentially expressed lncRNAs of 11 PCs and 31 PAs were validated by real-time quantitative PCR. RESULTS: On the microarray data between PC and PA samples (fold change ≥ 2, P < 0.05), 1809 differentially expressed lncRNAs and 1349 mRNAs also were identified. All carcinomas were clustered in the same group by clustering analysis using dysregulated lncRNAs or mRNAs. Four lncRNAs (LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly dysregulated in further RT-PCR validation. The global "lncRNA score" calculated from the lncRNAs above also differentiated parathyroid carcinomas from adenomas. CONCLUSIONS: LncRNA profiling shows distinct differentially expressed lncRNAs in parathyroid neoplasm. They may play a key role in parathyroid cancer and serve as potential biomarkers to distinguish parathyroid cancers from parathyroid adenomas.
Diagnosis of parathyroid carcinoma on histological examination is challenging. Thousands of differentially expressed lncRNAs were identified on the microarray data between parathyroid cancer and adenoma samples. Four lncRNAs were significantly dysregulated in further validation. The "lncRNA score" calculated from these lncRNAs differentiated parathyroid carcinomas from adenomas. LncRNAs serve as biomarkers for parathyroid cancer diagnosis. INTRODUCTION: Diagnosis of parathyroid carcinoma (PC) on histological examination is challenging. LncRNA profile study was conducted to find diagnostic biomarkers for PC. METHODS: LncRNA arrays containing 91,007 lncRNAs as well as 29,857 mRNAs were used to assess parathyroid specimen (5 carcinomas and 6 adenomas). Bioinformatics analyses were also conducted to compare the microarray results between parathyroid carcinomas and adenomas (PAs). Differentially expressed lncRNAs of 11 PCs and 31 PAs were validated by real-time quantitative PCR. RESULTS: On the microarray data between PC and PA samples (fold change ≥ 2, P < 0.05), 1809 differentially expressed lncRNAs and 1349 mRNAs also were identified. All carcinomas were clustered in the same group by clustering analysis using dysregulated lncRNAs or mRNAs. Four lncRNAs (LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly dysregulated in further RT-PCR validation. The global "lncRNA score" calculated from the lncRNAs above also differentiated parathyroid carcinomas from adenomas. CONCLUSIONS: LncRNA profiling shows distinct differentially expressed lncRNAs in parathyroid neoplasm. They may play a key role in parathyroid cancer and serve as potential biomarkers to distinguish parathyroid cancers from parathyroid adenomas.
Authors: Michael A Hahn; Viive M Howell; Anthony J Gill; Adele Clarkson; Graham Weaire-Buchanan; Bruce G Robinson; Leigh Delbridge; Oliver Gimm; Wolfgang D Schmitt; Bin T Teh; Deborah J Marsh Journal: Endocr Relat Cancer Date: 2010-02-18 Impact factor: 5.678
Authors: Mitchell Guttman; Ido Amit; Manuel Garber; Courtney French; Michael F Lin; David Feldser; Maite Huarte; Or Zuk; Bryce W Carey; John P Cassady; Moran N Cabili; Rudolf Jaenisch; Tarjei S Mikkelsen; Tyler Jacks; Nir Hacohen; Bradley E Bernstein; Manolis Kellis; Aviv Regev; John L Rinn; Eric S Lander Journal: Nature Date: 2009-02-01 Impact factor: 49.962
Authors: Gustavo G Fernandez-Ranvier; Elham Khanafshar; David Tacha; Mariwil Wong; Electron Kebebew; Quan-Yang Duh; Orlo H Clark Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: Filomena Cetani; Elena Ambrogini; Paolo Viacava; Elena Pardi; Giovanni Fanelli; Antonio Giuseppe Naccarato; Simona Borsari; Monica Lemmi; Piero Berti; Paolo Miccoli; Aldo Pinchera; Claudio Marcocci Journal: Eur J Endocrinol Date: 2007-05 Impact factor: 6.664
Authors: Willie Yu; John R McPherson; Mark Stevenson; Ronald van Eijk; Hong Lee Heng; Paul Newey; Anna Gan; Dina Ruano; Dachuan Huang; Song Ling Poon; Choon Kiat Ong; Tom van Wezel; Branca Cavaco; Steven G Rozen; Patrick Tan; Bin T Teh; Rajesh V Thakker; Hans Morreau Journal: J Clin Endocrinol Metab Date: 2014-11-11 Impact factor: 5.958